Skip to main content
PMC home page
Heart logoLink to Heart
. 1996 Nov;76(3 Suppl 3):53–59. doi: 10.1136/hrt.76.3_suppl_3.53

Neuroendocrine activation after myocardial infarction: causes and consequences

John G F Cleland 1, Peter J Cowburn 1, Kevin Morgan 2
PMCID: PMC484489  PMID: 8977365

Full text

PDF
53

Images in this article

54Image
on p.54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batin P. D., Hawkins M., Cowley A. J. Patterns of neuroendocrine activation at rest and during exercise following acute myocardial infarction. Eur Heart J. 1994 Nov;15(11):1552–1557. doi: 10.1093/oxfordjournals.eurheartj.a060429. [DOI] [PubMed] [Google Scholar]
  2. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987 Jan;57(1):17–22. doi: 10.1136/hrt.57.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonarjee V. V., Omland T., Nilsen D. W., Caidahl K., Sundsfjord J. A., Dickstein K. Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: relation to indices of cardiac and renal function. Br Heart J. 1995 Jun;73(6):511–516. doi: 10.1136/hrt.73.6.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bonarjee V. V., Omland T., Nilsen D. W., Carstensen S., Berning J., Edner M., Caidahl K. Left ventricular volumes, ejection fraction, and plasma proatrial natriuretic factor (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. CONSENSUS II Multi-Echo Study Group. Br Heart J. 1995 Jun;73(6):506–510. doi: 10.1136/hrt.73.6.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Broqvist M., Dahlström U., Karlberg B. E., Karlsson E., Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J. 1989 Dec;10(12):1075–1083. doi: 10.1093/oxfordjournals.eurheartj.a059429. [DOI] [PubMed] [Google Scholar]
  6. Choy A. M., Darbar D., Lang C. C., Pringle T. H., McNeill G. P., Kennedy N. S., Struthers A. D. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J. 1994 Jul;72(1):16–22. doi: 10.1136/hrt.72.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cleland J. G. ACE inhibitors for myocardial infarction: how should they be used? Eur Heart J. 1995 Feb;16(2):153–159. doi: 10.1093/oxfordjournals.eurheartj.a060879. [DOI] [PubMed] [Google Scholar]
  8. Cleland J. G. ACE inhibitors: current understanding and future directions. Br Heart J. 1994 Sep;72(3 Suppl):S1–S1. doi: 10.1136/hrt.72.3_suppl.s1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cleland J. G., Bulpitt C. J., Falk R. H., Findlay I. N., Oakley C. M., Murray G., Poole-Wilson P. A., Prentice C. R., Sutton G. C. Is aspirin safe for patients with heart failure? Br Heart J. 1995 Sep;74(3):215–219. doi: 10.1136/hrt.74.3.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cleland J. G., Dargie H. J. Heart failure, renal function, and angiotensin converting enzyme inhibitors. Kidney Int Suppl. 1987 May;20:S220–S228. [PubMed] [Google Scholar]
  11. Cleland J. G., Gillen G., Dargie H. J. The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur Heart J. 1988 Feb;9(2):132–141. doi: 10.1093/oxfordjournals.eurheartj.a062466. [DOI] [PubMed] [Google Scholar]
  12. Cleland J. G., Oakley C. M. Vascular tone in heart failure: the neuroendocrine-therapeutic interface. Br Heart J. 1991 Oct;66(4):264–267. doi: 10.1136/hrt.66.4.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cleland J. G., Puri S. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death? Br Heart J. 1994 Sep;72(3 Suppl):S81–S86. doi: 10.1136/hrt.72.3_suppl.s81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cleland J. G., Ward S., Dutka D., Habib F., Impallomeni M., Morton I. J. Stability of plasma concentrations of N and C terminal atrial natriuretic peptides at room temperature. Heart. 1996 Apr;75(4):410–413. doi: 10.1136/hrt.75.4.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dössegger L., Aldor E., Baird M. G., Braun S., Cleland J. G., Donaldson R., Jansen L. J., Joy M. D., Marin-Neto J. A., Nogueira E. Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre, double-blind, placebo-controlled trial. Eur Heart J. 1993 Jul;14 (Suppl 100):18–23. doi: 10.1093/eurheartj/14.suppl_c.18. [DOI] [PubMed] [Google Scholar]
  16. Falkenhahn M., Franke F., Bohle R. M., Zhu Y. C., Stauss H. M., Bachmann S., Danilov S., Unger T. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension. 1995 Feb;25(2):219–226. doi: 10.1161/01.hyp.25.2.219. [DOI] [PubMed] [Google Scholar]
  17. Fontana F., Bernardi P., Spagnolo N., Capelli M. Plasma atrial natriuretic factor in patients with acute myocardial infarction. Eur Heart J. 1990 Sep;11(9):779–787. doi: 10.1093/oxfordjournals.eurheartj.a059797. [DOI] [PubMed] [Google Scholar]
  18. Francis G. S., Benedict C., Johnstone D. E., Kirlin P. C., Nicklas J., Liang C. S., Kubo S. H., Rudin-Toretsky E., Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724–1729. doi: 10.1161/01.cir.82.5.1724. [DOI] [PubMed] [Google Scholar]
  19. Hall C., Rouleau J. L., Moyè L., de Champlain J., Bichet D., Klein M., Sussex B., Packer M., Rouleau J., Arnold M. O. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994 May;89(5):1934–1942. doi: 10.1161/01.cir.89.5.1934. [DOI] [PubMed] [Google Scholar]
  20. Hirvonen T., Remes J., Mustonen J., Tikkanen I., Tenhunen M., Pyörälä K. Effect of enalapril on plasma atrial natriuretic peptide in late recovery phase of acute myocardial infarction. Ann Med. 1991 Aug;23(3):271–275. doi: 10.3109/07853899109148059. [DOI] [PubMed] [Google Scholar]
  21. Hüttl S., Nussberger J., Lehmann K., Hasford J., Brunner H. R., Delius W. Beneficial clinical effect of very early enalapril treatment in patients with acute left ventricular failure complicating myocardial infarction. Clin Cardiol. 1995 Jun;18(6):317–323. doi: 10.1002/clc.4960180606. [DOI] [PubMed] [Google Scholar]
  22. Kettunen R. V., Leppäluoto J., Jounela A., Vuolteenaho O. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. Am Heart J. 1994 Jun;127(6):1449–1455. doi: 10.1016/0002-8703(94)90369-7. [DOI] [PubMed] [Google Scholar]
  23. Kingma J. H., van Gilst W. H., Peels C. H., Dambrink J. H., Verheugt F. W., Wielenga R. P. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). Eur Heart J. 1994 Jul;15(7):898–907. doi: 10.1093/oxfordjournals.eurheartj.a060608. [DOI] [PubMed] [Google Scholar]
  24. Lechleitner P., Genser N., Mair J., Maier J., Artner-Dworzak E., Dienstl F., Puschendorf B. Endothelin-1 in patients with complicated and uncomplicated myocardial infarction. Clin Investig. 1992 Dec;70(12):1070–1072. doi: 10.1007/BF00184545. [DOI] [PubMed] [Google Scholar]
  25. Lechleitner P., Genser N., Mair J., Maier J., Artner-Dworzak E., Dienstl F., Puschendorf B. Plasma immunoreactive endothelin in the acute and subacute phases of myocardial infarction in patients undergoing fibrinolysis. Clin Chem. 1993 Jun;39(6):955–959. [PubMed] [Google Scholar]
  26. Lerman A., Gibbons R. J., Rodeheffer R. J., Bailey K. R., McKinley L. J., Heublein D. M., Burnett J. C., Jr Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993 May 1;341(8853):1105–1109. doi: 10.1016/0140-6736(93)93125-k. [DOI] [PubMed] [Google Scholar]
  27. McCance A. J., Thompson P. A., Forfar J. C. Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease. Eur Heart J. 1993 Jun;14(6):751–757. doi: 10.1093/eurheartj/14.6.751. [DOI] [PubMed] [Google Scholar]
  28. McMurray J. J., Lang C. C., MacLean D., McDevitt D. G., Struthers A. D. Neuroendocrine changes post myocardial infarction: effects of xamoterol. Am Heart J. 1990 Jul;120(1):56–62. doi: 10.1016/0002-8703(90)90160-y. [DOI] [PubMed] [Google Scholar]
  29. Michorowski B., Ceremuzyński L. The renin-angiotensin--aldosterone system and the clinical course of acute myocardial infarction. Eur Heart J. 1983 Apr;4(4):259–264. doi: 10.1093/oxfordjournals.eurheartj.a061457. [DOI] [PubMed] [Google Scholar]
  30. Morita E., Yasue H., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T., Mukoyama M., Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993 Jul;88(1):82–91. doi: 10.1161/01.cir.88.1.82. [DOI] [PubMed] [Google Scholar]
  31. Motwani J. G., Fenwick M. K., McAlpine H. M., Kennedy N., Struthers A. D. Effectiveness of captopril in reversing renal vasoconstriction after Q-wave acute myocardial infarction. Am J Cardiol. 1993 Feb 1;71(4):281–286. doi: 10.1016/0002-9149(93)90791-a. [DOI] [PubMed] [Google Scholar]
  32. Motwani J. G., McAlpine H., Kennedy N., Struthers A. D. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 1993 May 1;341(8853):1109–1113. doi: 10.1016/0140-6736(93)93126-l. [DOI] [PubMed] [Google Scholar]
  33. Neuss M., Regitz-Zagrosek V., Hildebrandt A., Fleck E. Human cardiac fibroblasts express an angiotensin receptor with unusual binding characteristics which is coupled to cellular proliferation. Biochem Biophys Res Commun. 1994 Nov 15;204(3):1334–1339. doi: 10.1006/bbrc.1994.2609. [DOI] [PubMed] [Google Scholar]
  34. Ngo L., Vesely D. L., Bissett J. K., Murphy M. L., Dinh H., Sallman A. L., Rico D. M., Winters C. J., Wyeth R. P. Acute and sustained release of the atrial natriuretic factor prohormone N-terminus with acute myocardial infarction. Am J Med Sci. 1991 Mar;301(3):157–164. doi: 10.1097/00000441-199103000-00002. [DOI] [PubMed] [Google Scholar]
  35. Nio Y., Matsubara H., Murasawa S., Kanasaki M., Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995 Jan;95(1):46–54. doi: 10.1172/JCI117675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Omland T., Aakvaag A., Bonarjee V. V., Caidahl K., Lie R. T., Nilsen D. W., Sundsfjord J. A., Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996 Jun 1;93(11):1963–1969. doi: 10.1161/01.cir.93.11.1963. [DOI] [PubMed] [Google Scholar]
  37. Omland T., Aarsland T., Aakvaag A., Dickstein K. The effect of early converting enzyme inhibition on neurohumoral activation in acute myocardial infarction. Int J Cardiol. 1993 Nov;42(1):37–45. doi: 10.1016/0167-5273(93)90100-u. [DOI] [PubMed] [Google Scholar]
  38. Omland T., Aarsland T., Aakvaag A., Lie R. T., Dickstein K. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol. 1993 Aug 1;72(3):255–259. doi: 10.1016/0002-9149(93)90669-4. [DOI] [PubMed] [Google Scholar]
  39. Omland T., Bonarjee V. V., Lie R. T., Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am J Cardiol. 1995 Aug 1;76(4):230–235. doi: 10.1016/s0002-9149(99)80071-x. [DOI] [PubMed] [Google Scholar]
  40. Omland T., Bonarjee V. V., Nilsen D. W., Sundsfjord J. A., Lie R. T., Thibault G., Dickstein K. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J. 1993 Nov;70(5):409–414. doi: 10.1136/hrt.70.5.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Omland T., Lie R. T., Aakvaag A., Aarsland T., Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994 Apr;89(4):1573–1579. doi: 10.1161/01.cir.89.4.1573. [DOI] [PubMed] [Google Scholar]
  42. Omland T., Opstad K., Dickstein K. Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. Am Heart J. 1994 Apr;127(4 Pt 1):774–779. doi: 10.1016/0002-8703(94)90543-6. [DOI] [PubMed] [Google Scholar]
  43. Phillips P. A., Sasadeus J., Hodsman G. P., Horowitz J., Saltups A., Johnston C. I. Plasma atrial natriuretic peptide in patients with acute myocardial infarction: effects of streptokinase. Br Heart J. 1989 Feb;61(2):139–143. doi: 10.1136/hrt.61.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Pinto Y. M., van Gilst W. H., Kingma J. H., Schunkert H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol. 1995 Jun;25(7):1622–1626. doi: 10.1016/0735-1097(95)00090-q. [DOI] [PubMed] [Google Scholar]
  45. Puri S., Baker B. L., Dutka D. P., Oakley C. M., Hughes J. M., Cleland J. G. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation. 1995 Jun 1;91(11):2769–2774. doi: 10.1161/01.cir.91.11.2769. [DOI] [PubMed] [Google Scholar]
  46. Ray S. G., McMurray J. J., Morton J. J., Dargie H. J. Circulating endothelin in acute ischaemic syndromes. Br Heart J. 1992 May;67(5):383–386. doi: 10.1136/hrt.67.5.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ray S. G., Metcalfe M. J., Oldroyd K. G., Pye M., Martin W., Christie J., Dargie H. J., Cobbe S. M. Do radionuclide and echocardiographic techniques give a universal cut off value for left ventricular ejection fraction that can be used to select patients for treatment with ACE inhibitors after myocardial infarction? Br Heart J. 1995 May;73(5):466–469. doi: 10.1136/hrt.73.5.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Ray S. G., Morton J. J., Dargie H. J. Neuroendocrine activation and markers of early reperfusion in the acute phase of myocardial infarction. Eur Heart J. 1993 Dec;14(12):1615–1621. doi: 10.1093/eurheartj/14.12.1615. [DOI] [PubMed] [Google Scholar]
  49. Remes J., Tikkanen I., Fyhrquist F., Pyörälä K. Neuroendocrine activity in untreated heart failure. Br Heart J. 1991 May;65(5):249–255. doi: 10.1136/hrt.65.5.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Robalino B. D., Petrella R. W., Jubran F. Y., Bravo E. L., Healy B. P., Whitlow P. L. Atrial natriuretic factor in patients with right ventricular infarction. J Am Coll Cardiol. 1990 Mar 1;15(3):546–553. doi: 10.1016/0735-1097(90)90623-w. [DOI] [PubMed] [Google Scholar]
  51. Rouleau J. L., Packer M., Moyé L., de Champlain J., Bichet D., Klein M., Rouleau J. R., Sussex B., Arnold J. M., Sestier F. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994 Sep;24(3):583–591. doi: 10.1016/0735-1097(94)90001-9. [DOI] [PubMed] [Google Scholar]
  52. Rouleau J. L., de Champlain J., Klein M., Bichet D., Moyé L., Packer M., Dagenais G. R., Sussex B., Arnold J. M., Sestier F. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 1993 Aug;22(2):390–398. doi: 10.1016/0735-1097(93)90042-y. [DOI] [PubMed] [Google Scholar]
  53. Shyu K. G., Chen J. J., Shih N. L., Chang H., Wang D. L., Lien W. P., Liew C. C. Angiotensinogen gene expression is induced by cyclical mechanical stretch in cultured rat cardiomyocytes. Biochem Biophys Res Commun. 1995 Jun 6;211(1):241–248. doi: 10.1006/bbrc.1995.1802. [DOI] [PubMed] [Google Scholar]
  54. Sigurdsson A., Held P., Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J. 1993 Nov;126(5):1068–1076. doi: 10.1016/0002-8703(93)90656-t. [DOI] [PubMed] [Google Scholar]
  55. Sigurdsson A., Held P., Swedberg K., Wall B. Neurohormonal effects of early treatment with enalapril after acute myocardial infarction and the impact on left ventricular remodelling. Eur Heart J. 1993 Aug;14(8):1110–1117. doi: 10.1093/eurheartj/14.8.1110. [DOI] [PubMed] [Google Scholar]
  56. Stewart D. J., Kubac G., Costello K. B., Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991 Jul;18(1):38–43. doi: 10.1016/s0735-1097(10)80214-1. [DOI] [PubMed] [Google Scholar]
  57. Stoll M., Steckelings U. M., Paul M., Bottari S. P., Metzger R., Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995 Feb;95(2):651–657. doi: 10.1172/JCI117710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Sun Y., Weber K. T. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res. 1994 Nov;28(11):1623–1628. doi: 10.1093/cvr/28.11.1623. [DOI] [PubMed] [Google Scholar]
  59. Svanegaard J., Angelo-Nielsen K., Pindborg T. Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction. Br Heart J. 1992 Jul;68(1):38–42. doi: 10.1136/hrt.68.7.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Tomoda H. Atrial natriuretic peptide in acute myocardial infarction. Am J Cardiol. 1988 Nov 15;62(16):1122–1123. doi: 10.1016/0002-9149(88)90561-9. [DOI] [PubMed] [Google Scholar]
  61. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J. 1993 Mar;125(3):667–672. doi: 10.1016/0002-8703(93)90155-3. [DOI] [PubMed] [Google Scholar]
  62. Ullman B., Hulting J., Lundberg J. M. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J. 1994 Apr;15(4):454–461. doi: 10.1093/oxfordjournals.eurheartj.a060526. [DOI] [PubMed] [Google Scholar]
  63. Vaughan D. E., Lamas G. A., Pfeffer M. A. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol. 1990 Sep 1;66(5):529–532. doi: 10.1016/0002-9149(90)90476-h. [DOI] [PubMed] [Google Scholar]
  64. Weber K. T., Sun Y., Tyagi S. C., Cleutjens J. P. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 1994 Mar;26(3):279–292. doi: 10.1006/jmcc.1994.1036. [DOI] [PubMed] [Google Scholar]
  65. Whittaker P., Boughner D. R., Kloner R. A. Role of collagen in acute myocardial infarct expansion. Circulation. 1991 Nov;84(5):2123–2134. doi: 10.1161/01.cir.84.5.2123. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES